The HM13 Knockout A-549 Polyclonal Cells product offers a CRISPR/Cas9-edited polyclonal population of A-549 cells with targeted HM13 gene disruption, providing a heterogeneous knockout pool for loss-of-function studies. This polyclonal format preserves natural biological variability, avoiding clonal selection artifacts, and enables robust investigation of HM13-dependent processes in lung adenocarcinoma. The CRISPR/Cas9-mediated gene disruption creates a versatile model for dissecting mechanisms in cancer biology, immunology, and cellular stress responses without introducing single-cell biases.
The parental A-549 cell line, derived from a 58-year-old Caucasian male with lung adenocarcinoma, exhibits adherent epithelial morphology and serves as a well-established type II pneumocyte surrogate. Widely employed in lung cancer research, drug metabolism studies, and toxicological assays, A-549 cells provide a physiologically relevant context for interrogating HM13 function. Their tumorigenic background faithfully recapitulates key features of non-small cell lung cancer, including altered signaling pathways and immune evasion strategies, making them an ideal host for this knockout model.
HM13 encodes signal peptide peptidase, an ER-resident aspartyl protease that conducts intramembrane cleavage of signal peptides to generate HLA-E-binding epitopes, critical for immune surveillance via MHC class I antigen presentation. The protease also processes pre-proinsulin and presenilins (PSEN1 and PSEN2), linking it to insulin maturation and Notch signaling. HM13 activity is regulated by upstream ER stress transducers IRE1/XBP1 and ATF6, with the chaperone BiP, and functions within ER-associated degradation complexes containing DERL1, SELK, VIMP, and p97. Downstream effects include modulation of HLA-E peptide loading through TAP and B2M, positioning HM13 at the intersection of proteostasis, antigen processing, and UPR signaling.
In the A-549 cellular context, HM13 knockout allows precise dissection of immune evasion mechanisms, as lung cancers often exploit HLA-E to suppress cytotoxic lymphocyte responses. This model is particularly valuable for examining how HM13 loss impacts ER stress sensitivity, UPR-driven apoptosis, and presenilin-mediated Notch signaling within a type II pneumocyte background. The retained polyclonal heterogeneity better mirrors tumor microenvironment diversity, enhancing phenotypic assessments of HM13 deficiency in cancer progression and immunotherapy relevance.
Typical research applications include flow cytometric measurement of HLA-E surface expression, western blot and RT-qPCR validation of HM13 disruption, and transcriptome-wide RNA-seq to capture global gene expression changes. Researchers can utilize ER stress luciferase reporters, co-immunoprecipitation with DERL1 or PSEN1, and apoptosis assays under pharmacological ER stress induction. Functional assays such as migration/invasion testing and drug sensitivity profiling further support cancer immunotherapy target validation and preclinical modeling of graft-versus-host disease. For additional technical specifications and ordering details, please contact Ascent Research.
